Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS diseases [3] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX®2-73 targets SIGMAR1 and muscarinic receptors, aiming to restore cellular homeostasis and has demonstrated various beneficial properties in preclinical studies [3] Upcoming Events - Christopher U. Missling, PhD, President and CEO of Anavex, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1] - The conference will feature over 600 industry experts and corporate leaders from more than 225 healthcare companies, covering major healthcare verticals [2] Research and Development - Anavex has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of ANAVEX®2-73 for Parkinson's disease [3] - Another drug candidate, ANAVEX®3-71, is in clinical stages and shows promise in addressing Alzheimer's disease hallmarks in preclinical trials [3]